{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:36:16Z","timestamp":1774978576883,"version":"3.50.1"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Patient management following a multidisciplinary tumor board (MTB) recommendation has become standard of care in oncology and aims to ensure optimization and personalization of patient care. To assess the impact of MTB recommendations in clinical practice, adherence to the recommended procedures needs to be evaluated. Within this retrospective case series, we examined adherence rates to recommendations formulated at multidisciplinary myeloma tumor boards (MMTB) held at our institution. Specifically, we analyzed how often recommendations involving diagnostic procedures, therapies, and enrollment into clinical trials recommended by the MMTB were implemented. In addition, factors leading to non-adherence were evaluated. Methods: We reviewed all consecutive patient cases discussed at MMTBs held at the University Hospital of Bern, Switzerland, between 1 January and 31 December 2023. Adherence was assessed by systematically comparing all available clinical records with the recommendations formulated at the MMTBs. Results: In total, 218 patients were included in the study. Of all MMTB recommendations, 86% (n = 251) of all MMTB recommendations were followed. Of these, 84% (n = 244) were followed with complete adherence and 2% (n = 7) incompletely. All cases of non-implementation of MMTB recommendations concerning diagnostics or therapy were clinically justified. The main reason for non-adherence was patient decision. Other reasons included lack of cost coverage and relevant changes in the clinical scenario, including patient\u2019s death. In total, 36% (n = 104) of MMTB recommendations included clinical trial enrollment. However, study enrollment occurred only in 32% (n = 33) of the 104 cases. In 41% (n = 29) of the cases, justification for non-enrollment was documented in the clinical records. The most frequent reasons were patient decision, unmet inclusion criteria, delays in recruitment, lack of reimbursement, and changes in the clinical scenario. Conclusions: Our study showed an overall high level of adherence to MMTB recommendations for diagnostic procedures and therapy. However, only one third of recommendations for clinical trial enrollment were implemented, frequently due to patient decisions. Our results highlight the relevance of regular assessments of adherence rates to MTB recommendations and suggest that considering patient preferences in MTB discussions might minimize deviations.<\/jats:p>","DOI":"10.3390\/cancers17081297","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T10:05:51Z","timestamp":1744365951000},"page":"1297","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adherence to Multidisciplinary Tumor Board Recommendations in Patients with Multiple Myeloma"],"prefix":"10.3390","volume":"17","author":[{"given":"Val\u00e9rie","family":"Gennheimer","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1639-3059","authenticated-orcid":false,"given":"Dilara","family":"Akhoundova","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mich\u00e8le","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Jeker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yara","family":"Banz","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8771-947X","authenticated-orcid":false,"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[{"name":"Department of Hematology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"ref_1","unstructured":"(2024, December 05). Multiples Myelom (Plasmazellmyelom). Available online: https:\/\/www.krebsliga.ch\/ueber-krebs\/krebsarten\/multiples-myelom-plasmazellmyelom."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Gillich, C., Akhoundova, D., Hayoz, M., Aebi, Y., Largiad\u00e8r, C.R., Seipel, K., Daskalakis, M., Bacher, U., and Pabst, T. (2023). Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma. Cancers, 15.","DOI":"10.3390\/cancers15102699"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple Myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","first-page":"w14100","article-title":"Current Status and Updated Recommendations for Diagnosis and Treatment of Plasma Cell Myeloma in Switzerland","volume":"145","author":"Samaras","year":"2015","journal-title":"Swiss Med. Wkly."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple Myeloma: 2024 Update on Diagnosis, Risk-Stratification, and Management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00277-022-05051-y","article-title":"Multidisciplinary Tumor Board Analysis: Validation Study of a Central Tool in Tumor Centers","volume":"102","author":"Frank","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple Myeloma: Every Year a New Standard?","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102977","DOI":"10.1016\/j.critrevonc.2020.102977","article-title":"Current Concepts and Future Directions for Hemato-Oncologic Diagnostics","volume":"151","author":"Flach","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1055\/s-0043-100054","article-title":"Multidisziplin\u00e4re Tumorboards: Fakten und Zufriedenheitsanalyse eines unverzichtbaren Instruments von Tumorzentren","volume":"142","author":"Engelhardt","year":"2017","journal-title":"DMW\u2014Dtsch. Med. Wochenschr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00432-022-03991-6","article-title":"Guideline Adherence and Implementation of Tumor Board Therapy Recommendations for Patients with Gastrointestinal Cancer","volume":"149","author":"Krause","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11679","DOI":"10.1007\/s00432-023-05025-1","article-title":"Guideline Adherence of Tumor Board Recommendations in Lung Cancer and Transfer into Clinical Practice","volume":"149","author":"Walter","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ygyno.2009.12.005","article-title":"Addressing Clinical Trials: Can the Multidisciplinary Tumor Board Improve Participation? A Study from an Academic Women\u2019s Cancer Program","volume":"116","author":"Kuroki","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000506840","article-title":"A Retrospective Analysis of Clinical Trial Accrual of Patients Presented in a Multidisciplinary Tumor Board at a Tertiary Health Care Center and Associated Barriers","volume":"43","author":"Mobley","year":"2020","journal-title":"Oncol. Res. Treat."},{"key":"ref_15","unstructured":"(2024, December 09). NCCN Policy Priority\u2014Equity. Available online: https:\/\/www.nccn.org\/business-policy\/policy-and-advocacy-program\/policy-priorities\/policy-priority-equity."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/jama.2024.6281","article-title":"Survival Benefit Associated with Participation in Clinical Trials of Anticancer Drugs","volume":"331","author":"Iskander","year":"2024","journal-title":"JAMA"},{"key":"ref_17","unstructured":"(2024, November 21). Joining a Cancer Trial Doesn\u2019t Improve Survival Odds. Available online: https:\/\/www.science.org\/content\/article\/joining-cancer-trial-doesn-t-improve-survival-odds."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e7298","DOI":"10.1002\/cam4.7298","article-title":"Strategies for Increasing Accrual in Cancer Clinical Trials: What Is the Evidence?","volume":"13","author":"Michaels","year":"2024","journal-title":"Cancer Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7601","DOI":"10.1007\/s00432-022-04559-0","article-title":"Relevance of Tumor Boards for the Inclusion of Patients in Oncological Clinical Trials","volume":"149","author":"Dapper","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Hollunder, S., Herrlinger, U., Zipfel, M., Schmolders, J., Janzen, V., Thiesler, T., G\u00fcresir, E., Schr\u00f6ck, A., Far, F., and Pietsch, T. (2018). Cross-Sectional Increase of Adherence to Multidisciplinary Tumor Board Decisions. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4841-4"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"14775","DOI":"10.1007\/s00432-023-05253-5","article-title":"Adherence to Interdisciplinary Tumor Board Recommendations as an Expression of Quality-Assured Patient Care: Results of a Bicentric German Analysis","volume":"149","author":"Braulke","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.36401\/JQSH-23-22","article-title":"Quality Measures for Multidisciplinary Tumor Boards and Their Role in Improving Cancer Care","volume":"7","author":"Abuelgasim","year":"2024","journal-title":"Glob. J. Qual. Saf. Healthc."},{"key":"ref_23","first-page":"100838","article-title":"Clinical Management of Oligometastatic Cancer: Applying Multidisciplinary Tumor Board Recommendations in Practice","volume":"48","author":"Christ","year":"2024","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8197","DOI":"10.3390\/cimb46080484","article-title":"Rising Prevalence of Low-Frequency PPM1D Gene Mutations after Second HDCT in Multiple Myeloma","volume":"46","author":"Seipel","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Heini, A.D., Kammermann, K., Bacher, U., Jeker, B., Hayoz, M., Aebi, Y., Largiad\u00e8r, C.R., Nilius, H., and Pabst, T. (2024). Gender-Specific Prognostic Impact of Treosulfan Levels in High-Dose Chemotherapy for Multiple Myeloma. Cancers, 16.","DOI":"10.3390\/cancers16193364"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s12029-022-00847-7","article-title":"Adherence to Multidisciplinary Tumor Board Recommendations in Patients with Curable Esophageal and Gastric Cancers","volume":"54","author":"Soon","year":"2023","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1002\/cam4.3097","article-title":"Adherence of Head and Neck Squamous Cell Carcinoma Patients to Tumor Board Recommendations","volume":"9","author":"Rangabashyam","year":"2020","journal-title":"Cancer Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2147\/JMDH.S407908","article-title":"Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma","volume":"16","author":"Cao","year":"2023","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.anorl.2020.11.008","article-title":"Match between Therapeutic Proposal in Multidisciplinary Tumor Board and Actual Treatment in Head and Neck Cancer","volume":"138","author":"Alkasbi","year":"2021","journal-title":"Eur. Ann. Otorhinolaryngol. Head. Neck Dis."},{"key":"ref_30","first-page":"1","article-title":"Impact of GI Tumor Board on Patient Management and Adherence to Guidelines","volume":"4","author":"AlFarhan","year":"2018","journal-title":"J. Glob. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2217\/fon-2022-1183","article-title":"Physician Compliance with Multidisciplinary Tumor Board Recommendations for Managing Gynecological Cancers","volume":"19","author":"Naessens","year":"2023","journal-title":"Future Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/EDBK_243729","article-title":"Overcoming Barriers to Clinical Trial Enrollment","volume":"39","author":"Nipp","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1200\/JCO.2003.03.186","article-title":"Assessment of Differences in Patient Populations Selected for Excluded from Participation in Clinical Phase III Acute Myelogenous Leukemia Trials","volume":"21","author":"Mengis","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1740774520901514","article-title":"Discordant Attitudes and Beliefs about Cancer Clinical Trial Participation between Physicians, Research Staff, and Cancer Patients","volume":"17","author":"Hillyer","year":"2020","journal-title":"Clin. Trials"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/8\/1297\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:13:02Z","timestamp":1760029982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/8\/1297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17081297"],"URL":"https:\/\/doi.org\/10.3390\/cancers17081297","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}